Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

TELO

Telomir Pharmaceuticals Inc

Dec 13 • 04:00PM ET

5.20

Dollar change +0.11
Percentage change 2.16	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN AMGN GILD BMRN ALNY BIIB INCY EXEL NBIX

| Held by: VTI VXF IWO IWN VTWO IWC RSSL VTWG VTWV UWM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.79	Insider Own	42.66%	Shs Outstand	29.61M	Perf Week	-20.25%
Market Cap	153.97M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	16.98M	Perf Month	30.65%
Income	-23.02M	PEG	-	EPS next Q	-0.05	Inst Own	6.91%	Short Float	3.83%	Perf Quarter	-13.19%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	475.39%	Short Ratio	4.13	Perf Half Y	-5.45%
Book/sh	0.01	P/B	348.29	EPS next Y	-	ROA	-723.88%	Short Interest	0.65M	Perf Year	-
Cash/sh	0.03	P/C	185.51	EPS next 5Y	-	ROE	-1757.27%	52W Range	3.11 - 20.72	Perf YTD	4.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-5207.63%	52W High	-74.90%	Beta	-
Dividend TTM	-	Quick Ratio	1.74	Sales past 5Y	0.00%	Gross Margin	-	52W Low	67.20%	ATR (14)	0.65
Dividend Ex-Date	-	Current Ratio	1.74	EPS Y/Y TTM	-453.88%	Oper. Margin	-	RSI (14)	53.88	Volatility	14.36% 15.54%
Employees	9	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	12.15
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-250.00%	Payout	-	Rel Volume	3.38	Prev Close	5.09
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Nov 27	Avg Volume	157.46K	Price	5.20
SMA20	9.77%	SMA50	12.05%	SMA200	-4.77%	Trades		Volume	532,591	Change	2.16%

Dec-12-24 08:30AM	Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price (ACCESSWIRE)
Dec-03-24 07:30AM	Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1 (ACCESSWIRE) +14.82%
Nov-21-24 07:00AM	Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1 (ACCESSWIRE) +6.43%
Sep-26-24 04:00PM	Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday (ACCESSWIRE) +5.57%
Sep-04-24 07:30AM	Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications (ACCESSWIRE)
07:30AM	Loading…
Aug-20-24 07:30AM	Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs (ACCESSWIRE) -13.61%
Aug-12-24 08:30AM	Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman (GlobeNewswire) +15.62%
Jul-02-24 08:30AM	Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes (GlobeNewswire)
Jun-17-24 04:10PM	Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel (GlobeNewswire)
May-30-24 08:30AM	Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1 (GlobeNewswire) -7.62%
May-24-24 09:30AM	New to The Street TV Announces Episode 575 with its Four Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Saturday, May 25, 2024, at 6:30 PM ET (GlobeNewswire) +6.98%
May-16-24 09:30AM	Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support (GlobeNewswire)
May-13-24 10:53PM	TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace) -5.33%
May-07-24 03:02PM	Telomir Pharmaceuticals sees breakthrough potential in Anti-Aging Treatment with Telomir 1 (News Direct)
Apr-16-24 08:30AM	Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C. (GlobeNewswire) -5.32%
08:30AM	Loading…
Apr-02-24 08:30AM	Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024 (GlobeNewswire)
Mar-29-24 04:44PM	UPDATE Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines (GlobeNewswire)
Mar-26-24 08:30AM	Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines (GlobeNewswire)
Mar-22-24 08:30AM	Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th (GlobeNewswire)
Mar-14-24 08:30AM	Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal Science (GlobeNewswire) -9.83%
Mar-07-24 08:30AM	Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference (GlobeNewswire)
Mar-05-24 08:30AM	Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal (GlobeNewswire)
Feb-13-24 04:05PM	Telomir Pharmaceuticals Announces Closing of Initial Public Offering (GlobeNewswire) +12.16% +69.76%

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm's initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bay Shore Trust	10% Owner	Feb 13 '24	Buy	7.00	138,000	966,000	5,455,431	Feb 15 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TELO

Telomir Pharmaceuticals Inc

Upgrade your FINVIZ experience